GlassScriptPhysician profile
David A Minnick
NPI 1891897997
$1,917.44
in general payments reported to CMS, 2019-2025
18 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $183 · 2022: $40.31 · 2023: $179 · 2024: $185 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $376.01 | 2019-2025 | |
| Novo Nordisk INC | $277.71 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $231.32 | 2019-2020 | |
| Amgen INC. | $193.34 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $174.86 | 2019-2025 | Breztri |
| Stryker Corporation | $155.59 | 2025 | |
| Allergan, INC. | $143.04 | 2019-2020 | |
| Lilly USA, LLC | $98.27 | 2019-2025 | Mounjaro |
| Astellas Pharma US INC | $64.54 | 2019-2023 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.72 | 2019-2020 | |
| Abbvie INC. | $33.03 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $19.38 | 2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $19.17 | 2025 | |
| Soleno Therapeutics, INC. | $19.15 | 2025 | Vykat Xr |
| Ani Pharmaceuticals, INC. | $18.01 | 2025 | Purified Cortrophin Gel |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $15.64 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Minnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.